2024-11-08 - Analysis Report
## Thermo Fisher Scientific Inc (TMO) Stock Analysis

**1. Performance Comparison:**

Thermo Fisher Scientific Inc (TMO) is a global leader in providing scientific research and analysis instruments, services, and consumables. TMO has significantly outperformed the S&P 500 (VOO) with a cumulative return of 218.79% compared to VOO's 139.88%.  This translates to a difference of 78.91% which represents the 36.97th percentile of the historical performance range.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|-----|
| 2015-2017 | 48.2% | 14.4% | 18.0% | 1.1 |
| 2016-2018 | 61.3% | 17.3% | 36.6% | 1.1 |
| 2017-2019 | 126.1% | 17.3% | 83.0% | 1.1 |
| 2018-2020 | 141.4% | 24.6% | 102.3% | 0.8 |
| 2019-2021 | 204.1% | 24.6% | 114.3% | 0.8 |
| 2020-2022 | 68.7% | 26.2% | 51.0% | 0.8 |
| 2021-2023 | 12.5% | 33.2% | -16.3% | 0.9 |
| 2022-2024 | -13.2% | 31.0% | -36.9% | 0.9 |

This table shows that TMO has consistently outperformed the market (Alpha is positive) and has been less volatile than the market (Beta is slightly less than 1) in most of the historical periods. However, in recent years, the Beta has increased, suggesting a higher correlation with the market.

**2. Recent Price Movement:**

* **Closing Price:** 559.68
* **Last Market Price:** 557.91
* **5-day Moving Average:** 556.04
* **20-day Moving Average:** 574.43
* **60-day Moving Average:** 598.06

The stock price is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend.

**3. Technical Indicators:**

* **RSI:** 26.45 (Oversold)
* **PPO:** -0.1 (Sell Signal)
* **Recent (20-day) Relative Divergence:** -12.79 (Downward Trend)
* **Expected Return:** 46.46% (Long-term expected outperformance over S&P 500)

The RSI suggests the stock is currently oversold, while the PPO indicates a sell signal. The negative relative divergence shows a downward trend in the stock price. Despite this, the expected return remains high, suggesting potential long-term growth opportunities.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

The latest earnings report for the quarter ending November 2024 showed an EPS of 4.26, beating analyst expectations. The revenue also exceeded expectations. This suggests that the company is performing well despite the current market conditions.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.60B | 40.84% |
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |

TMO has shown consistent revenue growth and maintained a high profit margin, demonstrating a strong financial position and ability to generate profits.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $48.99B | 3.33% |
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |

The company has a healthy equity position and a stable ROE, further supporting its solid financial performance.

**6. News and Recent Issues:**

**Recent Earnings News:**

* **Earnings release:** TMO released its earnings for the quarter ending November 2024 on November 1st, 2024. The results beat analyst expectations, showing strong revenue growth and high profit margins. This news was reported by various financial news outlets, including Shacknews, Yahoo Finance, and MarketWatch.

**Market Outlook:**

* **Analysts' Opinions:** Many analysts remain optimistic about TMO's future prospects, citing the company's strong financial performance, growth potential in the life science market, and diverse business model. 
* **Performance Highlights:** TMO continues to be a top performer in the healthcare sector, benefiting from increasing demand for its products and services, especially in the pharmaceutical and biotechnology fields. 

**7. Comprehensive Analysis:**

TMO has demonstrated a strong track record of outperforming the market, with robust financials and consistently high revenue growth. Despite the current market volatility, the company's recent earnings beat expectations and its long-term prospects remain positive. However, the recent stock price movement, technical indicators, and relatively high Beta suggest that a period of consolidation or even short-term decline is possible.  

**Conclusion:**

Overall, TMO is a financially sound and fundamentally strong company with a promising future. While short-term fluctuations might occur, the long-term expected return remains high, making it a suitable investment for long-term investors looking for exposure to the healthcare sector. 

**Note:** This is a brief analysis based on the provided information. It is important to conduct thorough research, considering various factors such as industry trends, competitive landscape, and regulatory environment, before making any investment decisions. 
